Attached files
file | filename |
---|---|
EX-99.1 - EXHIBIT 99.1 - MultiCell Technologies, Inc. | exhibit99-1.htm |
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC 20549
_______________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
September 26, 2016
_______________________________________________________
MULTICELL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation)
68 Cumberland Street, Suite 301
Woonsocket, Rhode
Island 02895
(Address of principal executive offices, including zip
code)
(401) 762-0045
(Registrants telephone number,
including area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 8.01 | Other Events |
On September 26, 2016, the Companys majority owned subsidiary, MultiCell Immunotherapeutics, Inc. (MCIT), released a presentation concerning its therapeutic development platform (the MCIT Presentation). The MCIT Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The MCIT presentation and the information therein shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Exhibit No. | |
99.1 | The MCIT Presentation by MultiCell Immunotherapeutics, Inc. was released on September 26, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MULTICELL TECHNOLOGIES, INC.
W. Gerald Newmin
Chief
Executive Officer, Chief Financial Officer
Date: September 26, 2016